Your browser doesn't support javascript.
loading
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky, Peter C; Singer, Christian F; Egle, Daniel; Wette, Viktor; Petru, Edgar; Balic, Marija; Pichler, Angelika; Greil, Richard; Petzer, Andreas L; Bago-Horvath, Zsuzsanna; Fesl, Christian; Meek, Stephanie M; Kronenwett, Ralf; Rudas, Margaretha; Gnant, Michael; Filipits, Martin.
Affiliation
  • Dubsky PC; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Breast Center St. Anna, Lucerne, Switzerland. Electronic address: peter.dubsky@hirslanden.ch.
  • Singer CF; Department of Gynecology, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Egle D; Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.
  • Wette V; Breast Center, Brustzentrum Kärnten, St. Veit, Austria.
  • Petru E; Department of Gynecology and Obstetrics, Medical University Graz, Graz, Austria.
  • Balic M; Department of Internal Medicine, Division of Oncology, Medical University Graz, Graz, Austria.
  • Pichler A; Department of Hemato-Oncology, LKH Hochsteiermark-Leoben, Leoben, Austria.
  • Greil R; Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg, Sal
  • Petzer AL; Internal Medicine I, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinkum Linz Barmherzige Schwestern, Elisabethinen, Linz, Austria.
  • Bago-Horvath Z; Department of Pathology, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Fesl C; Department of Statistics, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
  • Meek SM; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Kronenwett R; Myriad International GmbH, Cologne, Germany.
  • Rudas M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Filipits M; Institute of Cancer Research, Department of Medicine I, Breast Health Center and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Eur J Cancer ; 134: 99-106, 2020 07.
Article de En | MEDLINE | ID: mdl-32502940
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Protocoles de polychimiothérapie antinéoplasique / Récepteurs à la progestérone / Récepteurs des oestrogènes / Récepteur ErbB-2 / Traitement néoadjuvant Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans / Middle aged Langue: En Journal: Eur J Cancer Année: 2020 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Protocoles de polychimiothérapie antinéoplasique / Récepteurs à la progestérone / Récepteurs des oestrogènes / Récepteur ErbB-2 / Traitement néoadjuvant Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans / Middle aged Langue: En Journal: Eur J Cancer Année: 2020 Type de document: Article Pays de publication: Royaume-Uni